Trethera News

Gloved hand of a scientist in a lab writing on a digital stilus with a digital pen.

Scientific microscope with visual representation of DNA helix

Trethera Announces Completion of $3.2 Million Seed Funding Round From Current Investors

February 24, 2021

Trethera closed a $3.2M seed funding round from existing investors, reinforcing confidence in TRE‑515. The funds will be used for working capital and support ongoing clinical-stage development.

Read More 

Trethera Announces FDA Orphan Drug Designation Granted to TRE-515 in the Treatment of Acute Disseminated Encephalomyelitis



January 7, 2021

Trethera announced FDA Orphan Drug Designation for TRE‑515 in acute disseminated encephalomyelitis (ADEM). This early-stage recognition offers incentives including trial design support, FDA grant eligibility, fee exemptions, and seven years of U.S. exclusivity.

Read More 

Globally Renowned Research Scientist Dr. Michael Shepard Joins Trethera’s Scientific Advisory Board



December 8, 2020

Trethera welcomed Dr. Michael Shepard, a Lasker Prize Laureate and pioneer in HER2-targeted therapy like Herceptin, to its Scientific Advisory Board. Dr. Shepard will advise on TRE‑515’s translational strategy in cancer and autoimmune disease.

Read More 

Trethera Announces U.S. Patent Application Filed for TRE-515, Extending Major Markets Exclusivity until 2041



November 2, 2020

Trethera filed a U.S. provisional patent application for the unique composition of TRE‑515, which, if granted, will provide global market exclusivity through 2041. IP counsel Wilson Sonsini Goodrich & Rosati led the filing strategy.

Read More 